Novo Nordisk wins FDA approval of Victoza for heart diseases in type 2 diabetes

FDA approval of Victoza : Danish pharma giant Novo Nordisk diabetes drug Victoza (liraglutide) has been approved by the U.S. Food and Drug Administration (FDA) for treating heart diseases in type 2 diabetes patients.

Victoza as per the latest pharma industry news has now been indicated in the US to cut down the risk of major adverse cardiovascular events like cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke and as well as established CV diseases in adult patients suffering from type 2 diabetes.

With its latest FDA approval, the Novo Nordisk diabetes drug Victoza, a human glucagon-like peptide-1 (GLP-1) analogue is now the first type 2 diabetes treatment to be available for physicians to help cut down the risk of major adverse cardiovascular events in their type 2 diabetes patients.

Victoza diabetes drug according to Novo Nordisk has an amino acid sequence 97% almost same as Glucagon-like peptide-1 (GLP-1), a 30 amino acid long peptide hormone.

Novo Nordisk Headquarters in Denmark

Novo Nordisk Headquarters in Denmark. Photo courtesy of Novo Nordisk A/S.

Novo Nordisk executive vice president and chief science officer Mads Krogsgaard Thomsen on the latest FDA approval of Victoza stated: “This approval marks an important milestone for millions of Americans living with type 2 diabetes, as cardiovascular disease is the number one cause of death in this patient population.

“Victoza now offers people with type 2 diabetes and established cardiovascular disease an effective treatment option to both lower their blood glucose and reduce their cardiovascular risk.”

The FDA approval for Victoza to be used for reducing risk of major adverse cardiovascular events in type 2 diabetes patients is based on the LEADER trial results. The global trial had established the superiority of Novo Nordisk diabetes drug in combination with standard of care in comparison to placebo when it came to reduction in the risk of cardiovascular death, non-fatal stroke or non-fatal heart attack.

It can be recalled that Victoza, which is currently available across 95 nations, was approved by the European Union in 2009 for type 2 diabetes treatment. A year later, the FDA approval for Victoza came about for the treatment of type 2 diabetes in the US as an adjunct to diet and exercise for better control of blood glucose levels.

CATEGORIES
TAGS
Share This